[CAS NO. 97322-87-7] Troglitazone

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [97322-87-7]

Catalog

HY-50935

Brand

MCE

CAS

97322-87-7

DESCRIPTION [97322-87-7]

Overview

MDL	MFCD00878416
Molecular Weight	441.54
Molecular Formula	C24H27NO5S
SMILES	O=C(SC1CC(C=C2)=CC=C2OCC3(C)OC(C(CC3)=C4C)=C(C)C(C)=C4O)NC1=O

For research use only. We do not sell to patients.

17 Publications Citing Use of MCE

Summary

Troglitazone is a PPARγ agonist, with EC ₅₀ s of 550 nM and 780 nM for human and murine PPARγ receptor, respectively.

IC50 & Target

PPARγ

550 nM (EC ₅₀ , Human PPARγ)

In Vitro

Troglitazone is a PPARγ agonist, with EC ₅₀ s of 550 nM and 780 nM for human and murine PPARγ receptor, respectively ^[1] . Troglitazone (2-200 μM) is cytotoxic to the pancreatic cancer cell lines (MIA Paca2 and PANC-1 cells), with IC ₅₀ s of 49.9 ± 1.2 and 51.3 ± 5.3 μM, respectively. Troglitazone (50 μM) increases chromatin condensation in MIA Paca2 and PANC-1 cells, enhances the activity of caspase-3 and decreases Bcl-2 expression ^[2] . Troglitazone (0, 1, 2, and 4 μM) sensitizes TRAIL-mediated apoptosis in human lung adenocarcinoma cells. Troglitazone enhancement of TRAIL-induced apoptosis is blocked by inhibition of autophagy, via activation of autophagy flux. In addition, the effects of troglitazone are induced by PPARγ activation in A549 cells ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Troglitazone (200 mg/kg, p.o.) shows inhibitory effects on the growth of tumor in the MIA Paca2 xenograft model ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00003058	Dana-Farber Cancer Institute\|National Cancer Institute (NCI)	Sarcoma	June 1997	Phase 2
NCT00116545	Parke-Davis\|National Institute on Aging (NIA)	Atherosclerosis\|Diabetes Mellitus	January 1997	Phase 2\|Phase 3

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 160 mg/mL ( 362.37 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.2648 mL	11.3240 mL	22.6480 mL
5 mM	0.4530 mL	2.2648 mL	4.5296 mL
10 mM	0.2265 mL	1.1324 mL	2.2648 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 0.5% CMC-Na >> 0.5% Tween-80

Solubility: 10 mg/mL (22.65 mM); Suspended solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (5.66 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (5.66 mM); Clear solution
4.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (5.66 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-

5-[[4-[(3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione

CS 045

Troglitazone

Romglizone

GR 92132X

CI 991

Rezulin

Noscal

Depotox